Exchange: NYSEArca·Updated 07:58 PM EST

XBI News

News
all
press releases
CAPR Stock Gains Ahead Of Weekend FDA Deramiocel Decision After Rough Week
The U.S. Food and Drug Administration is slated to decide on approving Capricor’s Deramiocel for the treatment of Duchenne muscular dystrophy by November 22.
Stocktwits
CAPR Stock Gains Ahead Of Weekend FDA Deramiocel Decision After Rough Week
The U.S. Food and Drug Administration is slated to decide on approving Capricor’s Deramiocel for the treatment of Duchenne muscular dystrophy by November 22.
Stocktwits
More News
Savara said the FDA’s review of Molgramostim is ongoing, but did not provide a revised date for the decision.
Stocktwits
Expected net proceeds of $140.6 million exceed September cash by $5.9 million and could reach $161.8 million if underwriters exercise their option.
Stocktwits
The offering price was still 74% above Monday’s close after positive leukemia trial results sent shares up 156% on Tuesday.
Stocktwits
New York’s pension fund held $1.42 billion in the three pharma giants versus just under $2 million in SLS and IBRX.
Stocktwits
Estimated approval odds are 62% for Capricor’s therapy, 85% for Savara’s drug facing the same Sunday target date, and 79% for Sanofi’s drug awaiting a Nov.25 decision.
Stocktwits
A $1,000 investment in SLS at the end of 2025 was worth about $5,080 at Tuesday’s close.
Stocktwits
Greenwich said two research abstracts related to its experimental breast cancer drug were accepted for the San Antonio Breast Cancer Symposium, scheduled for December 8 to 11.
Stocktwits
The trial also showed a median overall survival of 24 months compared with 14.7 months for patients receiving the best available treatment.
Stocktwits
ImmunityBio plans to present the full response rates at a medical meeting, showing how much benefit Anktiva added.
Stocktwits

Advertisement|Remove ads.